Critical appraisal of cabazitaxel in the management of advanced prostate cancer

Sumanta Kumar Pal1, Przemyslaw Twardowski1, Oliver Sartor21Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA; 2Departments of Urology and Medicine, Tulane University School of Medicine,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sumanta Kumar Pal, Przemyslaw Twardowski, Oliver Sartor
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Cabazitaxel castration resistant prostate cancer Jevtana breast cancer taxane Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/a20a2ea3de15461aadc529a7c6198457
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a20a2ea3de15461aadc529a7c6198457
record_format	dspace
spelling	oai:doaj.org-article:a20a2ea3de15461aadc529a7c61984572021-12-02T01:39:08ZCritical appraisal of cabazitaxel in the management of advanced prostate cancer1178-1998https://doaj.org/article/a20a2ea3de15461aadc529a7c61984572010-12-01T00:00:00Zhttps://www.dovepress.com/critical-appraisal-of-cabazitaxel-in-the-management-of-advanced-prosta-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Sumanta Kumar Pal1, Przemyslaw Twardowski1, Oliver Sartor21Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA; 2Departments of Urology and Medicine, Tulane University School of Medicine, New Orleans, LA, USAAbstract: Docetaxel remains a cornerstone of therapy for the patient with metastatic castration-resistant prostate cancer (CRPC). However, the landscape of CRPC therapy is changing rapidly – recently, data from the phase III TROPIC study revealed a survival advantage with the novel taxane cabazitaxel/prednisone (compared with mitoxantrone/prednisone) in a cohort of 755 men with docetaxel-refractory metastatic CRPC. Interestingly, cabazitaxel bears substantial structural similiarity to docetaxel but appears to be mechanistically distinct. In preclinical studies, the agent has antitumor activity in a variety of docetaxel-refractory in vitro and in vivo models. Subsequent to phase I testing in advanced solid tumors (where neutropenia was identified as a dose-limiting toxicity), the agent was assessed in a phase II trial in advanced, taxane-refractory breast cancer and in the aforementioned phase III TROPIC study. This review describes in detail the preclinical and clinical development of cabazitaxel.Keywords: cabazitaxel, castration resistant prostate cancer, Jevtana, breast cancer, taxaneSumanta Kumar PalPrzemyslaw TwardowskiOliver SartorDove Medical PressarticleCabazitaxelcastration resistant prostate cancerJevtanabreast cancertaxaneGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 5, Pp 395-402 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cabazitaxel castration resistant prostate cancer Jevtana breast cancer taxane Geriatrics RC952-954.6
spellingShingle	Cabazitaxel castration resistant prostate cancer Jevtana breast cancer taxane Geriatrics RC952-954.6 Sumanta Kumar Pal Przemyslaw Twardowski Oliver Sartor Critical appraisal of cabazitaxel in the management of advanced prostate cancer
description	Sumanta Kumar Pal1, Przemyslaw Twardowski1, Oliver Sartor21Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA; 2Departments of Urology and Medicine, Tulane University School of Medicine, New Orleans, LA, USAAbstract: Docetaxel remains a cornerstone of therapy for the patient with metastatic castration-resistant prostate cancer (CRPC). However, the landscape of CRPC therapy is changing rapidly – recently, data from the phase III TROPIC study revealed a survival advantage with the novel taxane cabazitaxel/prednisone (compared with mitoxantrone/prednisone) in a cohort of 755 men with docetaxel-refractory metastatic CRPC. Interestingly, cabazitaxel bears substantial structural similiarity to docetaxel but appears to be mechanistically distinct. In preclinical studies, the agent has antitumor activity in a variety of docetaxel-refractory in vitro and in vivo models. Subsequent to phase I testing in advanced solid tumors (where neutropenia was identified as a dose-limiting toxicity), the agent was assessed in a phase II trial in advanced, taxane-refractory breast cancer and in the aforementioned phase III TROPIC study. This review describes in detail the preclinical and clinical development of cabazitaxel.Keywords: cabazitaxel, castration resistant prostate cancer, Jevtana, breast cancer, taxane
format	article
author	Sumanta Kumar Pal Przemyslaw Twardowski Oliver Sartor
author_facet	Sumanta Kumar Pal Przemyslaw Twardowski Oliver Sartor
author_sort	Sumanta Kumar Pal
title	Critical appraisal of cabazitaxel in the management of advanced prostate cancer
title_short	Critical appraisal of cabazitaxel in the management of advanced prostate cancer
title_full	Critical appraisal of cabazitaxel in the management of advanced prostate cancer
title_fullStr	Critical appraisal of cabazitaxel in the management of advanced prostate cancer
title_full_unstemmed	Critical appraisal of cabazitaxel in the management of advanced prostate cancer
title_sort	critical appraisal of cabazitaxel in the management of advanced prostate cancer
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/a20a2ea3de15461aadc529a7c6198457
work_keys_str_mv	AT sumantakumarpal criticalappraisalofcabazitaxelinthemanagementofadvancedprostatecancer AT przemyslawtwardowski criticalappraisalofcabazitaxelinthemanagementofadvancedprostatecancer AT oliversartor criticalappraisalofcabazitaxelinthemanagementofadvancedprostatecancer
_version_	1718402976481017856

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

Ejemplares similares